Navigation Links
Cancer drugs in the pipeline
Date:12/11/2008

SAN ANTONIO - Scientists in the clinic and the laboratory continue to work to drive breast cancer mortality rates down with breakthrough drugs. With tamoxifen's discovery 30 years behind us, and the impact of Herceptin still being felt, researchers are studying zoledronic acid, aromatase inhibitors and monoclonal antibodies, among others, with encouraging results. Data will be presented at the CTRC-AACR San Antonio Breast Cancer Symposium.


Zoledronic Acid May Have Anti-Tumor Properties
Abstract #5101, Robert Coleman, M.D

Early results of the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial suggest that zoledronic acid may have antitumor properties when combined with chemotherapy. Treatment was linked with a reduction in tumor size (20.5 mm vs. 30 mm), an increase in the complete response rate (10.9 percent vs. 5.8 percent) and a decrease in the number of patients requiring mastectomy (65.3 percent vs. 77.9 percent).

Full release available/Complete data to be presented at the meeting.


Breast Cancer Patients May have Better Option to Reduce Estrogen Levels
Abstract #15, Stephen Jones, M.D
Embargo: 10:15 a.m. CST, December 11, 2008

Despite adjuvant therapy to reduce estrogen levels, one in five breast cancer survivors will have a recurrence. The first results from the TEAM study, one of the largest clinical trials ever conducted for invasive breast cancer, demonstrated that exemestane may be more effective in postmenopausal women than current treatment with tamoxifen. Exemestane is an agent that actually stops the body from producing estrogen.

Full data to be presented at the meeting.


Herceptin Increases Event-Free Survival in Locally Advanced HER2-Postive Breast Cancer
Abstract #31, Luca Gianni, M.D

Among patients with HER2-positive, locally advanced breast cancer, neoadjuvant treatment with Herceptin increased three-year, event-free survival to 70 percent compared with 53 percent among those receiving chemotherapy alone. The addition of trastuzumab (Herceptin) was well tolerated with acceptable cardiac safety. Researchers claim this phase III clinical trial establishes chemotherapy with one year of Herceptin as a standard treatment option in this patient population.

Full data to be presented at the meeting.


Lapatinib Improved Progression-Free Survival in Postmenopausal Women with Breast Cancer
Abstract #46, Stephen Johnston, Ph.D

For the treatment of women with hormone-receptor-positive metastatic breast cancer that also co-expressed HER2, combining lapatinib with an aromatase inhibitor significantly improved progression-free survival from three months in the letrozole alone group to 8.2 months in the combination group. Overall clinical benefit rate increased from 28.7 percent to 48.7 percent. Involving 1,286 patients, this is the largest trial of its kind to date.

Full data to be presented at the meeting.


Adjuvant Aromatase Inhibitors Lower Breast Cancer Recurrence Risk
Abstract #12, James Ingle, M.D.
Embargo: 9:30 a.m. CST, December 11, 2008

Adjuvant therapy with aromatase inhibitors (AIs) for postmenopausal estrogen-receptor-positive breast cancer given either as initial monotherapy or after several years of tamoxifen decreases the risk of recurrent disease more than tamoxifen, according to two meta-analyses. The risk reduction with AIs was statistically significant.

Full data to be presented at the meeting.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
2. Pilots May Face Greater Cancer Risk
3. Estrogen pills can benefit women with metastatic breast cancer
4. Light shines for potential early cancer diagnosis technique
5. LegalView Reports That Skin Cancer Drug May Offer Treatment to Mesothelioma Patients
6. PADRES Contra El Cancer to Host its 10th Annual Posada Holiday Celebration for Children with Cancer
7. UBC researchers discover gene mutation that causes eye cancer
8. Treadmill Desks More Effective in Decreasing Prostate Cancer Risks Than Vitamin and Antioxidant Supplements
9. Hormone therapy for prostate cancer does not appear to increase cardiac deaths
10. Oral cancer patients could be diagnosed earlier
11. PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... , ... The Congressional Budget Office (CBO) projects that the Better Care Reconciliation ... and Affordable Care Act (ACA), would result in 22 million Americans losing their health ... More than 20 million Americans have gained health insurance under the ACA, and from ...
(Date:6/27/2017)... , ... June 27, 2017 , ... A January 18th ... projected to reach a staggering $6.81 billion by the year 2024 according to a ... a faster rate than those made from titanium. Los Angeles area clinic Beverly Hills ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... experts to contribute to an upcoming case studies guidebook. This guidebook offers an ... , This book will include articles, case studies and how-to’s that fall into ...
(Date:6/27/2017)... ... June 27, 2017 , ... Dr. Richard Amato, a respected ... his practice, Advanced Periodontics and Dental Implant Center of Connecticut. As part of the ... waiting areas. The renovations are intended to improve patient comfort while making it possible ...
(Date:6/27/2017)... North Hollywood, CA (PRWEB) , ... June 27, ... ... on orthodontic treatments . Orthodontics is a dental specialty that focuses on ... other appliances. Benefits include improved aesthetics and function. , North Hollywood ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... -- The Cincinnati location of Diplomat ... DPLO), has been awarded a Top Workplaces 2017 ... are based on an employee survey administered by WorkplaceDynamics, LLC, ... The survey measures several aspects of workplace culture, including alignment, ... ...
(Date:5/30/2017)... , May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... data solutions, today announced that it will be presenting at the ... 8:00 AM PT. Erez Raphael , CEO, of DarioHealth will ... conference will be held on June 6th & 7th, 2017 at ... in the small / micro-cap space. ...
(Date:5/26/2017)... BARBARA, Calif. , May 25, 2017  In ... United States , Direct Relief is working with ... overdose-reversing Naloxone available at no cost to community health ... other nonprofit providers nationwide. "Pfizer has ... access to medicines and ensuring patient safety through educational ...
Breaking Medicine Technology: